Patents by Inventor Vikram SADINENI

Vikram SADINENI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTIBODY
    Publication number: 20240091354
    Abstract: This provides pharmaceutical compositions that comprise a combination of an anti-cancer agent which is an first antibody and a second antibody. In some embodiments, the first antibody is an anti-Programmed Death-1 (PD-1) antibody. In certain embodiments, the composition is a fixed dose formulation. In certain embodiments, the composition is administered as a flat-dose. The disclosure also provides a kit for treating a subject afflicted with a disease, the kit comprising a dosage of any composition disclosed herein and instructions for using the composition in any of the disclosed methods for treating a disease.
    Type: Application
    Filed: March 27, 2023
    Publication date: March 21, 2024
    Applicant: Bristol-Myers Squibb Company
    Inventors: Vikram SADINENI, Yong QUAN, Wallace KASERER
  • Combination therapy comprising nivolumab and ipilimumab
    Patent number: 11612654
    Abstract: This provides pharmaceutical compositions that comprise a combination of an anti-cancer agent which is an first antibody and a second antibody. In some embodiments, the first antibody is an anti-Programmed Death-1 (PD-1) antibody. In certain embodiments, the composition is a fixed dose formulation. In certain embodiments, the composition is administered as a flat-dose. The disclosure also provides a kit for treating a subject afflicted with a disease, the kit comprising a dosage of any composition disclosed herein and instructions for using the composition in any of the disclosed methods for treating a disease.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: March 28, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yong Quan, Vikram Sadineni, Wallace Kaserer
  • COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTIBODY
    Publication number: 20200197518
    Abstract: This provides pharmaceutical compositions that comprise a combination of an anti-cancer agent which is an first antibody and a second antibody. In some embodiments, the first antibody is an anti-Programmed Death-1 (PD-1) antibody. In certain embodiments, the composition is a fixed dose formulation. In certain embodiments, the composition is administered as a flat-dose. The disclosure also provides a kit for treating a subject afflicted with a disease, the kit comprising a dosage of any composition disclosed herein and instructions for using the composition in any of the disclosed methods for treating a disease.
    Type: Application
    Filed: December 20, 2019
    Publication date: June 25, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Vikram SADINENI, Yong QUAN, Wallace KASERER
  • Compositions comprising a combination of nivolumab and ipilimumab
    Patent number: 10512689
    Abstract: This provides pharmaceutical compositions that comprise a combination of an anti-cancer agent which is an first antibody and a second antibody. In some embodiments, the first antibody is an anti-Programmed Death-1 (PD-1) antibody. In certain embodiments, the composition is a fixed dose formulation. In certain embodiments, the composition is administered as a flat-dose. The disclosure also provides a kit for treating a subject afflicted with a disease, the kit comprising a dosage of any composition disclosed herein and instructions for using the composition in any of the disclosed methods for treating a disease.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: December 24, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vikram Sadineni, Yong Quan, Wallace Kaserer
  • COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTIBODY
    Publication number: 20170143827
    Abstract: This provides pharmaceutical compositions that comprise a combination of an anti-cancer agent which is an first antibody and a second antibody. In some embodiments, the first antibody is an anti-Programmed Death-1 (PD-1) antibody. In certain embodiments, the composition is a fixed dose formulation. In certain embodiments, the composition is administered as a flat-dose. The disclosure also provides a kit for treating a subject afflicted with a disease, the kit comprising a dosage of any composition disclosed herein and instructions for using the composition in any of the disclosed methods for treating a disease.
    Type: Application
    Filed: November 30, 2016
    Publication date: May 25, 2017
    Applicant: Bristol-Myers Squibb Company
    Inventors: Vikram SADINENI, Yong Quan, Wallace Kaserer
  • COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTIBODY
    Publication number: 20160304607
    Abstract: This provides pharmaceutical compositions that comprise a combination of an anti-cancer agent which is an first antibody and a second antibody. In some embodiments, the first antibody is an anti-Programmed Death-1 (PD-1) antibody. In certain embodiments, the composition is a fixed dose formulation. In certain embodiments, the composition is administered as a flat-dose. The disclosure also provides a kit for treating a subject afflicted with a disease, the kit comprising a dosage of any composition disclosed herein and instructions for using the composition in any of the disclosed methods for treating a disease.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Applicant: Bristol-Myers Squibb Company
    Inventors: Vikram SADINENI, Yong Quan, Wallace Kaserer